PL2618842T3 - Nowa metoda immunostymulacyjna - Google Patents

Nowa metoda immunostymulacyjna

Info

Publication number
PL2618842T3
PL2618842T3 PL11826223T PL11826223T PL2618842T3 PL 2618842 T3 PL2618842 T3 PL 2618842T3 PL 11826223 T PL11826223 T PL 11826223T PL 11826223 T PL11826223 T PL 11826223T PL 2618842 T3 PL2618842 T3 PL 2618842T3
Authority
PL
Poland
Prior art keywords
new
immunostimulating method
new immunostimulating
immunostimulating
Prior art date
Application number
PL11826223T
Other languages
English (en)
Inventor
David Charles Jackson
Amabel Tan
Weiguang Zeng
Original Assignee
Ena Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010904284A external-priority patent/AU2010904284A0/en
Application filed by Ena Therapeutics Pty Ltd filed Critical Ena Therapeutics Pty Ltd
Publication of PL2618842T3 publication Critical patent/PL2618842T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11826223T 2010-09-22 2011-09-22 Nowa metoda immunostymulacyjna PL2618842T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2010904284A AU2010904284A0 (en) 2010-09-22 Novel Immunostimulatory Method
AU2011902408A AU2011902408A0 (en) 2011-06-20 Novel immunstimulatory method
EP11826223.7A EP2618842B1 (en) 2010-09-22 2011-09-22 Novel immunostimulatory method
PCT/AU2011/001225 WO2012037612A1 (en) 2010-09-22 2011-09-22 Novel immunostimulatory method

Publications (1)

Publication Number Publication Date
PL2618842T3 true PL2618842T3 (pl) 2019-10-31

Family

ID=45873313

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20155567.9T PL3669892T3 (pl) 2010-09-22 2011-09-22 Kompozycja do zastosowania w metodzie immunostymulacyjnej
PL11826223T PL2618842T3 (pl) 2010-09-22 2011-09-22 Nowa metoda immunostymulacyjna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL20155567.9T PL3669892T3 (pl) 2010-09-22 2011-09-22 Kompozycja do zastosowania w metodzie immunostymulacyjnej

Country Status (10)

Country Link
US (5) US9676819B2 (pl)
EP (3) EP3669892B1 (pl)
JP (6) JP2013537892A (pl)
CN (2) CN105477640B (pl)
AU (1) AU2011305061B2 (pl)
CA (1) CA2811957C (pl)
DK (1) DK2618842T3 (pl)
ES (2) ES2735274T3 (pl)
PL (2) PL3669892T3 (pl)
WO (1) WO2012037612A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012037612A1 (en) 2010-09-22 2012-03-29 The University Of Melbourne Novel immunostimulatory method
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
US20170274068A1 (en) * 2014-09-12 2017-09-28 The University Of Melbourne Immunological reagent
US10253062B2 (en) 2014-12-23 2019-04-09 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
US11464853B2 (en) 2016-02-26 2022-10-11 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
CN118161614A (zh) * 2017-03-31 2024-06-11 艾娜呼吸私人有限公司 用tlr2激动剂治疗呼吸道感染
PL3728289T3 (pl) 2017-12-21 2026-01-26 Axelia Oncology Pty Ltd Zoptymalizowane związki
EP3727372A4 (en) * 2017-12-21 2021-10-27 Ena Therapeutics Pty Ltd ADMINISTRATION OF A TLR2 AGONIST TO TREAT OR PREVENT AN INFECTIOUS RESPIRATORY DISEASE
JP2022539091A (ja) 2019-06-26 2022-09-07 アクセリア オンコロジー ピーティーワイ リミテッド 新規な分子
AU2020343725A1 (en) * 2019-09-04 2022-03-24 Axelia Oncology Pty Ltd Cancer treatment
CN114364378A (zh) * 2019-09-04 2022-04-15 阿克塞利阿肿瘤学私人有限公司 癌症免疫疗法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4119856A1 (de) 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
ES2311478T3 (es) 1999-11-19 2009-02-16 Csl Limited Composiciones de vacuna contra el hcv.
WO2001090129A2 (en) 2000-05-19 2001-11-29 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
EP1382352A1 (de) * 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung
BR0313154A (pt) * 2002-08-12 2005-08-02 Council The Queensland Inst Of Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b
CN101113178A (zh) 2002-08-12 2008-01-30 昆士兰医学研究所理事会 包含辅助t细胞和细胞毒性t淋巴细胞(ctl)表位的新免疫原性脂肽
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
CN1921877A (zh) * 2004-01-16 2007-02-28 悉生物有限公司 陪伴蛋白10对Toll样受体诱导的细胞因子和趋化因子分泌的调节
US20060002941A1 (en) 2004-01-23 2006-01-05 Vievax Corp. Compositions comprising immune response altering agents and methods of use
WO2005079419A2 (en) 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP2460533A3 (en) 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP1666056A1 (en) 2004-12-06 2006-06-07 Bestewil Holding B.V. Cancer vaccine vesicles
WO2006069262A2 (en) 2004-12-21 2006-06-29 Vaxinnate Corporation Compositions of influenza viral proteins and methods of use thereof
US20100129385A1 (en) * 2005-02-08 2010-05-27 Jackson David C Immunogenic molecules
JP2008531502A (ja) 2005-02-22 2008-08-14 ザ レジェンツ オブ ザ ユニバーシティ オブ カリフォルニア 胃腸の炎症を処置する方法
EP1787660A1 (en) 2005-11-22 2007-05-23 GBF Gesellschaft für Biotechnologische Forschung mbH New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
US20080170996A1 (en) 2006-07-28 2008-07-17 The Board Of Regents Of The University Of Texas System Compositions and Methods for Stimulation of Lung Innate Immunity
AU2014202674B2 (en) 2007-05-04 2014-08-14 Marina Biotech, Inc. Amino acid lipids and uses thereof
DK2200638T3 (en) * 2007-10-09 2016-06-06 Univ Melbourne Compositions for the transfection of cells
WO2009137103A2 (en) 2008-05-09 2009-11-12 Ourth Donald D Anti-cancer/anti-viral compounds and methods of use
WO2009155332A1 (en) * 2008-06-17 2009-12-23 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
WO2010028246A2 (en) 2008-09-05 2010-03-11 Id Biomedical Corporation Of Quebec Novel compositions and adjuvants
WO2010093436A2 (en) 2009-02-11 2010-08-19 Carson Dennis A Toll-like receptor modulators and treatment of diseases
AU2010229835B2 (en) 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
JP2012523379A (ja) 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
GB0907989D0 (en) 2009-05-08 2009-06-24 Hybrid Systems Ltd Multivalent adjuvant display
EP2338521A1 (en) 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2012037612A1 (en) 2010-09-22 2012-03-29 The University Of Melbourne Novel immunostimulatory method
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
US20170274068A1 (en) 2014-09-12 2017-09-28 The University Of Melbourne Immunological reagent
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
JP2016216593A (ja) 2015-05-19 2016-12-22 株式会社リコー 反応材、熱交換器及びケミカルヒートポンプ
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
US11464853B2 (en) 2016-02-26 2022-10-11 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
PT3429618T (pt) 2016-03-16 2024-04-02 Amal Therapeutics Sa Combinação de um modulador de ponto de controlo imunitário e um complexo que compreende um péptido de penetração celular, uma carga e um agonistra peptídico de tlr para utilização em medicina
CN118161614A (zh) 2017-03-31 2024-06-11 艾娜呼吸私人有限公司 用tlr2激动剂治疗呼吸道感染
NL2018803B1 (en) 2017-04-27 2018-11-05 Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc Adjuvant compounds
EA202090319A1 (ru) 2017-08-30 2020-10-16 Окленд Юнисервисиз Лимитед Пептидные конъюгаты, способ конъюгации и их использование
EP3727372A4 (en) 2017-12-21 2021-10-27 Ena Therapeutics Pty Ltd ADMINISTRATION OF A TLR2 AGONIST TO TREAT OR PREVENT AN INFECTIOUS RESPIRATORY DISEASE
PL3728289T3 (pl) 2017-12-21 2026-01-26 Axelia Oncology Pty Ltd Zoptymalizowane związki
JP2022539091A (ja) 2019-06-26 2022-09-07 アクセリア オンコロジー ピーティーワイ リミテッド 新規な分子
CN114364378A (zh) 2019-09-04 2022-04-15 阿克塞利阿肿瘤学私人有限公司 癌症免疫疗法
AU2020343725A1 (en) 2019-09-04 2022-03-24 Axelia Oncology Pty Ltd Cancer treatment
EP4157255A4 (en) 2020-05-26 2024-07-03 Ena Respiratory Pty Ltd CORONAVIRUS TREATMENT
AU2021294603A1 (en) 2020-06-26 2022-12-15 Ena Respiratory Pty Ltd Branched lipid compounds

Also Published As

Publication number Publication date
EP3669892B1 (en) 2024-05-08
WO2012037612A1 (en) 2012-03-29
US9676819B2 (en) 2017-06-13
JP2023113902A (ja) 2023-08-16
JP2017061504A (ja) 2017-03-30
EP3669892C0 (en) 2024-05-08
CN105477640A (zh) 2016-04-13
US20240050364A1 (en) 2024-02-15
EP3520814A1 (en) 2019-08-07
AU2011305061A1 (en) 2013-05-02
JP6657507B2 (ja) 2020-03-04
EP2618842B1 (en) 2019-04-24
US20220296505A1 (en) 2022-09-22
US20130230544A1 (en) 2013-09-05
PL3669892T3 (pl) 2024-10-07
EP3669892A1 (en) 2020-06-24
CN105477640B (zh) 2019-09-17
CN103189072B (zh) 2018-02-09
CA2811957A1 (en) 2012-03-29
US20190380952A1 (en) 2019-12-19
US12569431B2 (en) 2026-03-10
ES2980738T3 (es) 2024-10-02
CN103189072A (zh) 2013-07-03
AU2011305061B2 (en) 2016-04-14
EP2618842A1 (en) 2013-07-31
ES2735274T3 (es) 2019-12-17
US10406100B2 (en) 2019-09-10
JP2025143357A (ja) 2025-10-01
EP2618842A4 (en) 2014-03-26
US11351114B2 (en) 2022-06-07
JP2013537892A (ja) 2013-10-07
DK2618842T3 (da) 2019-07-01
JP2021130713A (ja) 2021-09-09
JP7497962B2 (ja) 2024-06-11
CA2811957C (en) 2019-04-16
US11786458B2 (en) 2023-10-17
US20170246312A1 (en) 2017-08-31
JP2019167369A (ja) 2019-10-03

Similar Documents

Publication Publication Date Title
FI20105641A7 (fi) Uusi menetelmä mikroselluloosan valmistamiseksi
BR112012015988A2 (pt) método
GB201305501D0 (en) Performing a multiply-multiply-accumulate instruction
GB201001833D0 (en) Method
FI20105642A7 (fi) Uusi menetelmä mikroselluloosan valmistamiseksi
GB201010439D0 (en) A method
IL224973B (en) Composition for muscle repair and regeneration
GB201007353D0 (en) Method
GB201004759D0 (en) Method
GB201011513D0 (en) Method
GB201007354D0 (en) Method
BR112013009024A2 (pt) método
BR112012023891A2 (pt) método
GB201006306D0 (en) Method
PL2651915T3 (pl) Ciągły związek arycykliczny
FR2967178B1 (fr) Volet de desenfumage a portillon
GB201010855D0 (en) Method
BR112012033000A2 (pt) método
BR112013015580A2 (pt) método de radioestabilização
KR101209432B9 (ko) 복근재활기구
FI20105128L (fi) Menetelmä pigmentti-kuitukomposiitin valmistamiseksi
IL222550A (en) Method for diagnosing melanocytic proliferations
GB201007207D0 (en) Method
DK2576237T3 (da) A drawing tool
GB201007522D0 (en) Method